MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma

P. de la Puente, B. Muz, A. Jin, F. Azab, M. Luderer, N. N. Salama, A. K. Azab

Research output: Contribution to journalLetterpeer-review

12 Scopus citations
Original languageEnglish
Pages (from-to)e399
JournalBlood cancer journal
StatePublished - Feb 26 2016

Cite this